{"url_path":"/sec/iova/8-k/2026-07-02/item-8-01","section_key":"item-8-01","section_title":"Item 8.01 **","topic":"sec","document":{"doc_type":"8-K","doc_date":"2026-07-02","source_url":"https://www.sec.gov/Archives/edgar/data/1425205/0001104659-26-080409-index.html","accession_number":"0001104659-26-080409","cik":"0001425205","ticker":"IOVA","issuer_name":"IOVANCE BIOTHERAPEUTICS, INC.","edgar_url":"https://www.sec.gov/Archives/edgar/data/1425205/0001104659-26-080409-index.html","primary_entity_key":"0001425205","primary_entity_name":"IOVANCE BIOTHERAPEUTICS, INC."},"word_count":57,"has_tables":true,"body_markdown":"**Item 8.01**\n**Other Events.**\n\n \n\nOn June 30, 2026, Iovance Biotherapeutics, Inc.\n(the “Company”) updated its corporate presentation that it uses for presentations at healthcare conferences and to analysts,\ncurrent stockholders, and others. A copy of the Company’s presentation that it intends to use at such events is attached as Exhibit 99.1\nand is incorporated herein by reference."}